Download Powerpoint

Increasing Regulatory T Cells With Interleukin-2 and
Interleukin-2 Antibody Complexes Attenuates Lung
Inflammation and Heart Failure ProgressionNovelty and
Significance
by Huan Wang, Lei Hou, Dongmin Kwak, John Fassett, Xin Xu, Angela Chen, Wei
Chen, Bruce R. Blazar, Yawei Xu, Jennifer L. Hall, Jun-bo Ge, Robert J. Bache, and
Yingjie Chen
Hypertension
Volume 68(1):114-122
June 8, 2016
Copyright © American Heart Association, Inc. All rights reserved.
End-stage congestive heart failure (CHF) exhibits robust leukocyte infiltration in lungs and
moderate leukocyte infiltration in hearts.
Huan Wang et al. Hypertension. 2016;68:114-122
Copyright © American Heart Association, Inc. All rights reserved.
IL2/JES6-1 treatment attenuates progression of congestive heart failure (CHF) in mice with
existing left ventricle (LV) failure.
Huan Wang et al. Hypertension. 2016;68:114-122
Copyright © American Heart Association, Inc. All rights reserved.
IL2/JES6-1 treatment significantly reduces lung inflammatory cytokines and mildly affects LV
inflammatory cytokines in mice with existing left ventricle (LV) failure.
Huan Wang et al. Hypertension. 2016;68:114-122
Copyright © American Heart Association, Inc. All rights reserved.
IL2/JES6-1 treatment suppresses immune cell infiltration in the lung of mice with existing left
ventricle (LV) failure.
Huan Wang et al. Hypertension. 2016;68:114-122
Copyright © American Heart Association, Inc. All rights reserved.
IL2/JES6-1 treatment attenuates lung fibrosis in mice with existing left ventricle (LV) failure.
Huan Wang et al. Hypertension. 2016;68:114-122
Copyright © American Heart Association, Inc. All rights reserved.
IL2/JES6-1 treatment attenuates the development of transverse aortic constriction (TAC)–
induced left ventricular (LV) hypertrophy and cardiac dysfunction.
Huan Wang et al. Hypertension. 2016;68:114-122
Copyright © American Heart Association, Inc. All rights reserved.